Table 4 |
||||||
|
Number of changesa from initialb to stablec therapy by condition for initial treatments (drug(s) and dose) prescribed to ≥ 10 patients |
||||||
|
Initial treatment |
Patients |
Changes to stable therapy |
||||
|
|
|
|||||
|
Drug (dose) |
Treated (% all treated) |
Followed >1 year (% treated) |
Stable in 1 year (% followed) |
Mean |
Median |
Range |
|
|
||||||
|
Post-herpetic neuralgia |
||||||
|
Amitriptyline hydrochloride (10 mg per day) |
93 (6.6) |
50 (53.8) |
9 (18.0) |
2.6 |
2 |
1–5 |
|
Amitriptyline hydrochloride (10 mg not specified) |
65 (4.6) |
36 (55.4) |
4 (11.1) |
4.8 |
5 |
2–8 |
|
Amitriptyline hydrochloride (25 mg per day) |
64 (4.5) |
39 (60.9) |
10 (25.6) |
2.6 |
3 |
1–5 |
|
Codeine phosphate (8 mg)+paracetamol (500 mg not specified) |
34 (2.4) |
21 (61.8) |
9 (42.9) |
4 |
2 |
1–12 |
|
Co-dydramol (not specified) Dihydrocodeine tartrate (10 mg)+paracetamol (500 mg) |
30 (2.1) |
20 (66.7) |
7 (35.0) |
5.6 |
4 |
1–18 |
|
Codeine phosphate (30 mg)+paracetamol (500 mg not specified) |
24 (1.7) |
15 (62.5) |
5 (33.3) |
5.4 |
5 |
1–9 |
|
Capsaicin (0.025% 4 times a day) |
19 (1.3) |
15 (78.9) |
6 (40.0) |
2.8 |
2 |
1–6 |
|
Carbamazepine (200 mg per day) |
19 (1.3) |
12 (63.2) |
7 (58.3) |
4 |
4 |
1–8 |
|
Paracetamol (500 mg not specified) |
18 (1.3) |
14 (77.8) |
4 (28.6) |
2.8 |
2 |
1–6 |
|
Co-proxamol (not specified) Dextropropoxyphene hydrochloride (32.5 mg)+paracetamol (325 mg) |
17 (1.2) |
11 (64.7) |
2 (18.2) |
5 |
5 |
3–7 |
|
|
||||||
|
Trigeminal neuralgia |
||||||
|
Carbamazepine (200 mg per day) |
103 (8.8) |
67 (65.0) |
9 (13.4) |
3.7 |
3 |
1–10 |
|
Amitriptyline hydrochloride (10 mg per day) |
53 (4.6) |
35 (66.0) |
6 (17.1) |
2 |
2 |
1–4 |
|
Amitriptyline hydrochloride (10 mg not specified) |
43 (3.7) |
33 (76.7) |
3 (9.1) |
1.3 |
1 |
1–2 |
|
Carbamazepine (300 mg per day) |
35 (3.0) |
22 (62.9) |
8 (36.4) |
2.1 |
2 |
1–4 |
|
Carbamazepine (100 mg not specified) |
33 (2.8) |
19 (57.6) |
4 (21.1) |
1.5 |
2 |
1–2 |
|
Amitriptyline hydrochloride (25 mg per day) |
31 (2.7) |
17 (54.8) |
4 (23.5) |
3.5 |
3 |
2–6 |
|
Carbamazepine (100 mg per day) |
30 (2.6) |
22 (73.3) |
4 (18.2) |
2.5 |
2 |
1–5 |
|
Carbamazepine (400 mg per day) |
29 (2.5) |
23 (79.3) |
5 (21.7) |
4.8 |
2 |
1–16 |
|
Gabapentin (300 mg per day) |
21 (1.8) |
14 (66.7) |
5 (35.7) |
2.8 |
3 |
1–4 |
|
Codeine phosphate (8 mg)+paracetamol (500 mg not specified) |
20 (1.7) |
12 (60.0) |
3 (25.0) |
5.7 |
6 |
5–6 |
|
Codeine phosphate (30 mg)+paracetamol (500 mg not specified) |
19 (1.6) |
13 (68.4) |
4 (30.8) |
2 |
1 |
1–5 |
|
Co-proxamol (not specified) Dextropropoxyphene hydrochloride (32.5 mg)+paracetamol (325 mg) |
14 (1.2) |
11 (78.6) |
1 (9.1) |
1 |
1 |
1-1 |
|
|
||||||
|
Painful diabetic neuropathy |
||||||
|
Amitriptyline hydrochloride (10 mg per day) |
72 (7.8) |
35 (48.6) |
4 (11.4) |
1.5 |
2 |
1–2 |
|
Amitriptyline hydrochloride (25 mg per day) |
41 (4.4) |
25 (61.0) |
7 (28.0) |
3 |
2 |
1–11 |
|
Amitriptyline hydrochloride (10 mg not specified) |
35 (3.8) |
21 (60.0) |
2 (9.5) |
1 |
1 |
1-1 |
|
Gabapentin (900 mg per day) |
30 (3.3) |
15 (50.0) |
5 (33.3) |
5.2 |
4 |
2–12 |
|
Co-dydramol (not specified) Dihydrocodeine tartrate (10 mg)+paracetamol (500 mg) |
21 (2.3) |
15 (71.4) |
4 (26.7) |
2.8 |
1 |
1–8 |
|
Paracetamol (500 mg not specified) |
20 (2.2) |
11 (55.0) |
1 (9.1) |
1 |
1 |
1-1 |
|
Codeine phosphate (8 mg)+paracetamol (500 mg not specified) |
18 (2.0) |
13 (72.2) |
1 (7.7) |
2 |
2 |
2-2 |
|
|
||||||
|
aTreatment changes comprised each switch, discontinuation, new treatment or addition of a concomitant treatment, but not a change in dose. bStarted within 28 days of the first record of the disease. cMore than two prescriptions for the same treatment with less than 56 days between each one. |
||||||
|
Hall et al. BMC Family Practice 2008 9:26 doi:10.1186/1471-2296-9-26 |
||||||
